Drivers of Discontinuation of Oral PrEP Within Europe: Findings From a Real-World Survey of PrEP Use

<u>Melanie Schroeder¹, Fritha Hennessy², Libby Turner², Tim Holbrook², Ama Appiah¹, Jenny Scherzer³</u> ¹ViiV Healthcare, Brentford, United Kingdom; ²Adelphi Real World, Bollington, United Kingdom; ³ViiV Healthcare, Munich, Germany

Key Takeaways

- Data were drawn from the Adelphi pre-exposure prophylaxis (PrEP) Disease Specific Programme[™], a real-world, crosssectional survey conducted across five European countries (France, Germany, Italy, Spain and the United Kingdom), to describe physicians' perspectives on current PrEP options, as well as physician-reported information on individuals' PrEP use, satisfaction and reasons for discontinuation.
- There was high physician and PrEP user satisfaction (physicianreported) with oral PrEP; however, suboptimal adherence was cited as a primary driver of dissatisfaction across both assessments.
- The most frequent physician-reported reasons for PrEP discontinuation included suboptimal adherence and issues around taking oral medications every day.
- Key drivers of future PrEP prescription included the availability of long-acting medications and individuals changing their sexual behaviour

Background


- Oral PrEP is a highly effective, guideline-recommended method for preventing new HIV acquisitions when taken and adhered to as prescribed,^{1–3} and has been demonstrated to reduce transmission by up to 93% in real-world effectiveness studies.⁴
- Despite the high effectiveness of oral PrEP, barriers to widespread uptake and adherence remain, including issues such as stigma, fear of inadvertent disclosure, contraindications or intolerance, and limitations in access.⁵
- Previous analyses have reported high physician satisfaction with current oral PrEP options; however, medication cost, suboptimal adherence and unsuitability for individuals with renal comorbidities were cited as limitations.⁶
- Since the Adelphi PrEP Disease Specific Programme[™] survey was conducted, long-acting cabotegravir has been approved for PrEP, and it has the potential to address issues around adherence and uptake in populations not effectively supported with current oral PrEP options.⁶
- Using data from a real-world, cross-sectional survey, we describe physicians' perspectives on current PrEP options, as well as physician-reported information on individuals' PrEP use, satisfaction and reasons for discontinuation.

Methods

- Data were collected from the Adelphi PrEP Disease Specific Programme[™],⁷⁻ a real-world, cross-sectional survey with retrospective data collection (Figure 1), conducted between November 2022 and June 2023 in five European countries (France, Germany, Italy, Spain and the United Kingdom)
- Infectious disease specialists and primary care physicians who treated ≥10 people receiving PrEP each month were asked to provide their perspectives on current PrEP options, as well as details on the next 6 people consulted who were receiving PrEP (referred to as "PrEP users" throughout) and 4 people not currently receiving PrEP but who would benefit from it (referred to as "PrEP non-users" throughout)
- All data are summarised descriptively.

Figure 1. Overview of the Disease Specific Programme[™] (DSP)

Adelphi PrEP DSP[™], a real-world cross-sectional survey*



*Red indicates components of the DSP[™] methodology included in the present analysis.

19th European AIDS Conference; October 18-21, 2023; Warsaw, Poland

Results

- Overall, 189 physicians provided information for 1884 individuals, of whom 1105 were PrEP users and 779 were PrEP non-users (Table 1).
- Most individuals (PrEP users; PrEP non-users) were White (83%; 83%), male (sex at birth) (85%; 81%) and homosexual (70%; 63%), with a median age of 34 and 33 years, respectively.

Table 1. Baseline Characteristics of PrEP Users and PrEP Non-Users


% unless otherwise specified	PrEP use category		Quarall
	PrEP users (n=1105)	PrEP non-users (n=779)	Overall (N=1884)
Age Median (IQR), years	34 (28–42)	33 (27–42)	33 (28–42)
Sex	34 (20-42)	33 (27-42)	55 (20–42)
Female	13.6	17.7	15.3
Male	85.2	80.7	83.3
Intersex	1.3	1.5	1.4
Gender identity			
Cisgender	89.1	90.4	89.6
Transgender	6.7	6.2	6.5
Nonbinary or gender queer	2.1	2.6	2.3
Other	2.1	0.9	1.6
Sexuality			
Homosexual	70.3	63.0	67.3
Heterosexual	15.9	22.1	18.5
Bisexual or pansexual	13.8	14.9	14.2
Country			
France	29.0	27.6	28.5
Germany	21.6	20.7	21.2
Spain	21.7	21.3	21.5
Italy	19.9	23.2	21.3
United Kingdom	7.7	7.2	7.5
Ethnicity (question not asked in France)*	00.0	00.0	00 7
White/Caucasian	82.8	82.6	82.7
Hispanic/Latinx Afro-Caribbean	10.7	9.4	10.2
Asian (Indian subcontinent)	3.4 0.8	5.0 1.2	4.1 1.0
South-East Asian	0.8	0.7	0.7
Asian (other)	0.9	0.4	0.7
Middle Eastern	0.5	0.5	0.5
Other	0.1	0.2	0.1
BMI [†]	0.1	0.2	0.1
Median (IQR), kg/m²	23.9 (22.2–25.8)	23.7 (22.2–25.9)	23.9 (22.2–25.9)
Probability of acquiring HIV [‡]	· · · · /		
No probability	-	2.4	_
Mild probability	-	11.7	_
Moderate probability	-	29.0	-
Severe probability	-	40.3	-
Very severe probability	_	16.6	_

*PrEP users, n=784; PrEP non-users, n=564. †PrEP users, n=1095; PrEP non-users, n=771. ‡Physician perception. BMI, body mass index; IQR, interquartile range.

Figure 2. Physician Satisfaction With Current Oral PrEP Options (A) and **Reasons for Dissatisfaction (B)**

A. Satisfaction with current oral PrEP options (n=185)

B. Top 5 reasons for dissatisfaction (n=33)



STI, sexually transmitted infection.

- High physician satisfaction with current oral PrEP options was observed (87% somewhat or very satisfied; Figure 2A).
- Reasons for physician dissatisfaction included the fact that PrEP does not protect against other sexually transmitted infections (52%), the cost of medication (48%) and suboptimal adherence observed with daily PrEP (48%; Figure 2B).

Acknowledgments: Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi PrEP Disease Specific Programme[™], sponsored by multiple pharmaceutical companies, of which ViiV Healthcare was one. ViiV Healthcare did not influence the original survey through either contribution to the design of questionnaires or data collection. The authors thank everyone who has contributed to the success of the Adelphi PrEP Disease Specific Programme[™], including all study participants and their families and the clinical investigators and their staff. Editorial assistance was provided by Euan Paul at Scimentum (Nucleus Global), with funding provided by ViiV Healthcare.

Did not want to take a pill every day ndividual did not think they were at risk of Concerns around HIV-related stigma Did not think PrEP was 100% effective

acquiring HIV

associated with PrEP

Privacy and confidentiality concerns


Did not have easy access to PrEP

providers

Concerns around safety

Lack of education on PrEP 5%

Unknown



References: 1. U.S. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2023. Available from: https://clinicalinfo.hiv.gov/en/guidelines. Accessed September 2023. 2. European AIDS Clinical Society. Guidelines Version 11.1. 2022. Available from: https://www.eacsociety.org/media/guidelines-11.1_final_09-10.pdf. Accessed September 2023 3. International Antiviral Society–USA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society–USA Panel. 2022. Available from: https://www.iasusa.org/resources/guidelines/. Accessed September 2023. 4. Jourdain H, et al. Lancet Public Health. 2022;7(6):e529-e536. 5. Muhumuza R, et al. Arch Sex Behav. 2021;50(4):1729-1742. 6. Schroeder M, et al. AIDS Impact 2023. 7. Anderson P, et al. Curr Med Res Opin. 2008;24(11):3063–3072. 8. Babineaux SM, et al. BMJ Open. 2016;6(8):e010352. 9. Higgins V, et al. Diabetes Metab Syndr Obes. 2016;9:371–380.

Don't know

PrEP non-users (n=60)
PrEP users (n=107)

40%

14%

10%

17%

COVID-19 lockdown/guarantine

Was tired of taking oral medication

Personal request to stop PrEP

Inconvenience of required testing

Inconvenience of daily dosing

every 3 months

every day

Changed lifestyle and sexual behaviour

resulting in lowered risk of HIV acquisition

30%

25%

21%

16%

16%

9%

PrEP non-users (n=44)

Suboptimal adherence





• Of those who were likely to be prescribed PrEP in the future, the availability of long-acting medications was cited as the most common reason that would lead to an individual receiving PrEP.

• For those who were unlikely to receive PrEP in the future in the absence of an alternative option being available, the most common reason was the individual not wanting to take daily oral medication.

• The introduction of long-acting PrEP could provide an alternative option addressing some of the limitations of current PrEP options, including stigma, fear of inadvertent disclosure and the requirement of taking daily pills.

• Further research based on PrEP user/non-user reported data will be the subject of future publications, as physician-reported data may not completely capture the perspectives of the individual.



This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their licence. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.

19th European AIDS Conference; October 18-21, 2023; Warsaw, Poland